![Michael Greve](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Greve
Algemeen Directeur bij ATEVIA AG
Oorsprong van het eerstegraads netwerk van Michael Greve
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Subsidiary | Internet Software/Services | 4 | |
Kizoo Technology Capital GmbH
![]() Kizoo Technology Capital GmbH Investment ManagersFinance Kizoo Technology Capital GmbH (KIZOO) is the venture capital arm of Atevia AG, itself a subsidiary of Cinetic Gesellschaft zur Entwicklung & Vertrieb von Medien. The firm was founded by Michael Greve, Matthias Hornberger, and Frank Schüler in 2006. It is headquartered in Karlsruhe, Germany.
3
| Subsidiary | Investment Managers | 3 |
Atevia Immobilien Management GmbH
![]() Atevia Immobilien Management GmbH Investment ManagersFinance Part of Cinetic Gesellschaft zur Entwicklung & Vertrieb von Medien, Atevia Immobilien Management GmbH is an alternative investment manager. The company is based in Karlsruhe, Germany. The CEOs are Matthias Hornberger, Michael Greve. The German company was founded in 2008.
3
| Subsidiary | Investment Managers | 3 |
Atevia Immobilien Objekte GmbH & Co. KG
![]() Atevia Immobilien Objekte GmbH & Co. KG Real Estate DevelopmentFinance Atevia Immobilien Objekte GmbH & Co. KG provides real estate services. The private company is based in Karlsruhe, Germany. The CEOs of the German company are Frank Schüler, Michael Greve, Matthias Hornberger.
2
| Private Company | Real Estate Development | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Michael Greve via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Union College (New York) | College/University | Graduate Degree | |
University of St. Gallen | College/University | Masters Business Admin | |
University of Basel | College/University | Graduate Degree | |
Zürcher Kantonalbank (Broker)
![]() Zürcher Kantonalbank (Broker) Investment Banks/BrokersFinance Zürcher Kantonalbank (Broker) (ZKB-Broker) is the brokerage business unit of Zürcher Kantonalbank, a state-owned full-service bank founded in 1870, which is headquartered in Zurich, Switzerland. They conduct all investment activities in-house including financial advisory services, research, trading, and asset management. ZKB-Broker is an active trader in securities, foreign currencies, banknotes, precious metals, commodity contracts and financial derivatives on their own account and on behalf of third-party customers. The bank provides underwriting services in domestic debt and equity markets, sales and trading of listed domestic warrants and structured derivatives, and Swiss Franc foreign exchange trading. The firm offers round-the-clock market-making in credit default swaps from Swiss issuers. Their research covers a broad international investment universe and maintains a successful equity, bonds and sustainability research capability, together with independent investment fund research. | Investment Banks/Brokers | Analyst-Equity | |
BioMedPartners AG
![]() BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector. | Investment Managers | Private Equity Investor | |
Miracor Medical SA
![]() Miracor Medical SA Electronic Equipment/InstrumentsElectronic Technology Miracor Medical SA engages in the development and manufacture of medical devices. Its product PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System has a driving console and associated catheters to improve outcomes for severe heart attack patients. It seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after a heart attack. The company was founded by Werner Mohl in May, 2008 and is headquartered in Vienna, Austria. | Electronic Equipment/Instruments | Director/Board Member | |
Cell Medica Switzerland AG
![]() Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Karlsruher Institut für Technologie | College/University | Undergraduate Degree | |
Jomed AG | Corporate Officer/Principal | ||
APEIRON Biologics AG
![]() APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | Biotechnology | Corporate Officer/Principal | |
Hansjörg Reiter GmbH | Chief Executive Officer | ||
705 West GmbH | Chief Executive Officer Chief Executive Officer | ||
Zumbach & Reiter PartGmbB | Corporate Officer/Principal | ||
Atevia Immobilien Stein GmbH | Chief Executive Officer Chief Executive Officer | ||
Atevia Immobilien Tela GmbH | Chief Executive Officer Chief Executive Officer | ||
BC Platforms AG
![]() BC Platforms AG Data Processing ServicesTechnology Services BC Platforms AG provides powerful genomic data management and analysis solutions. It offers pharmaceutical, biobank, healthcare and academia products. The company was founded by Timo Kanninen in 1997 and is headquartered in Basel, Switzerland. | Data Processing Services | Director/Board Member | |
JFG Life Sciences Stiftung der Universität Basel
![]() JFG Life Sciences Stiftung der Universität Basel Investment Trusts/Mutual FundsMiscellaneous JFG Life Sciences Stiftung der Universität Basel engages in the promotion of innovation transfer in the field of life sciences and related areas. It also supports knowledge and technology transfer at the University of Basel. The company was founded on December 20, 2018 and is headquartered Basel, Switzerland. | Investment Trusts/Mutual Funds | Chief Executive Officer | |
Cyclarity Therapeutics, Inc.
![]() Cyclarity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cyclarity Therapeutics, Inc. provides technology to treat, cure, and reverse atherosclerosis. It develops simple and direct interventions targeting toxic forms of cholesterol using rationally designed molecules to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration. The company was founded by Michael Kope and Matthew O?Connor and is headquartered in Mountain View, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Revel Pharmaceuticals, Inc.
![]() Revel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Revel Pharmaceuticals, Inc. engages in the provision of therapeutic designer enzymes to degrade molecular damage that accumulates with aging. The company was founded by Aaron Cravens, David Spiegel and Jason Crawford in 2019 and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
LIfT BioSciences Ltd.
![]() LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Miscellaneous Commercial Services | Director/Board Member | |
Vaximm AG
![]() Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
Zwitserland | 11 |
Duitsland | 7 |
Verenigde Staten | 4 |
België | 2 |
Oostenrijk | 2 |
Sectoraal
Health Technology | 5 |
Consumer Services | 5 |
Commercial Services | 4 |
Finance | 3 |
Electronic Technology | 2 |
Operationeel
Chief Executive Officer | 13 |
Director/Board Member | 9 |
Corporate Officer/Principal | 5 |
Investor Relations Contact | 3 |
Graduate Degree | 2 |
Sterkste connecties
- Beurs
- Insiders
- Michael Greve
- Bedrijfsconnecties